Grant: Operating Grant
University of Toronto
$246,633.00
Community Engagement in HIV Vaccine Research: Advancing HIV Vaccine Trial Preparedness among Men who have Sex with Men in India
EF 2009-10
Résumé
The best hope for ending AIDS is a vaccine. HIV vaccine development depends on clinical trials, which ultimately must include human volunteers at risk for HIV. The mission of the Canadian HIV Vaccine Initiative includes meaningful engagement of vulnerable populations in the developing world in HIV vaccine research. With 95% of people living with HIV (PLHIV) in developing countries, we must ensure the vaccine works where HIV causes the most harm. India has the second highest number of PLHIV in the world; HIV disproportionately affects men who have sex with men (MSM), their male and female partners, and children. With initial HIV vaccine trials planned among MSM in India, we and our community-based collaborators believe it is vital to empower MSM communities to make informed choices and advocate for their needs and rights in HIV vaccine trials. A contentious history of biomedical research, and differences in power and culture between trial sponsors and local communities, presents challenges to meaningful involvement of MSM in HIV research.
This 3-year study is guided by critical ethnography both to describe what currently exists and to advocate for and empower MSM. Sites: Chennai and Mumbai. Phase 1 (qualitative): 6 focus groups with MSM (n=48), in-depth interviews with community advocates/service providers (n=12) to explore HIV vaccine/clinical trial knowledge, attitudes, beliefs and "local vaccination cultures." Phase 2 (quantitative): theory-informed survey, supported by Phase 1, among 600 MSM to assess willingness to participate (WTP) in HIV vaccine trials and determinants of WTP. Phase 3: participatory action research with 200 MSM through community forums to critically assess and share research findings and support community-based action agendas for follow-up.
Project goals are to build capacity and support advocacy among diverse MSM to ensure ethically and fairly conducted clinical trials, advancing the goals of the Canadian HIV Vaccine Initiative.
Programme
Operating Grant
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
190339
Name
Newman Peter A
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Gender and Health
Theme2
Social / Cultural / Environmental / Population Health
Prcname2
Gender, Sex & Health
Projecttitle
Community Engagement in HIV Vaccine Research: Advancing HIV Vaccine Trial Preparedness among Men who have Sex with Men in India
Programtype2
Operating Grants
Orgnameinp2
University of Toronto
Cihramount2
$246,633
Cihrequipment2
$0
Programname2
Operating Grant
Keyworddelim
Clinical Trials; Critical Ethnography; Hiv Vaccine; Men Who Have Sex With Men; Mixed Methods Research; Research Participation
Abstract
The best hope for ending AIDS is a vaccine. HIV vaccine development depends on clinical trials, which ultimately must include human volunteers at risk for HIV. The mission of the Canadian HIV Vaccine Initiative includes meaningful engagement of vulnerable populations in the developing world in HIV vaccine research. With 95% of people living with HIV (PLHIV) in developing countries, we must ensure the vaccine works where HIV causes the most harm. India has the second highest number of PLHIV in the world; HIV disproportionately affects men who have sex with men (MSM), their male and female partners, and children. With initial HIV vaccine trials planned among MSM in India, we and our community-based collaborators believe it is vital to empower MSM communities to make informed choices and advocate for their needs and rights in HIV vaccine trials. A contentious history of biomedical research, and differences in power and culture between trial sponsors and local communities, presents challenges to meaningful involvement of MSM in HIV research.
This 3-year study is guided by critical ethnography both to describe what currently exists and to advocate for and empower MSM. Sites: Chennai and Mumbai. Phase 1 (qualitative): 6 focus groups with MSM (n=48), in-depth interviews with community advocates/service providers (n=12) to explore HIV vaccine/clinical trial knowledge, attitudes, beliefs and "local vaccination cultures." Phase 2 (quantitative): theory-informed survey, supported by Phase 1, among 600 MSM to assess willingness to participate (WTP) in HIV vaccine trials and determinants of WTP. Phase 3: participatory action research with 200 MSM through community forums to critically assess and share research findings and support community-based action agendas for follow-up.
Project goals are to build capacity and support advocacy among diverse MSM to ensure ethically and fairly conducted clinical trials, advancing the goals of the Canadian HIV Vaccine Initiative.
Competitiondate
200909
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Newman, Peter A
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $246,633~ $0~